News & Events

Breaking News– Vivli announces the AMR Surveillance Open Data Re-use Challenge, funded by Wellcome, to Initiate April 19th

Vivli is launching the Vivli AMR Surveillance Open Data Re-use Challenge, funded by Wellcome, on 19th April 2023. The data challenge aims to stimulate and support the innovative re-use of surveillance data available in the AMR Register.

This Challenge provides an opportunity for multidisciplinary teams to win prizes by using high-quality industry AMR surveillance data to answer pressing research questions. The data will be shared through the AMR Register.

A series of prizes can be won by research teams from any discipline who find new insights in the data and contributes to the fight against antimicrobial resistance.

What prizes can be won?
There are five monetary awards:
• Grand Prize Award – $20,000
• 4 awards – $10,000 (each) in the categories of Innovation and Impact

Winning teams will additionally be provided with funding towards expenses for ECCMID 2024 if an abstract is accepted.

Sign up to the data challenge Slack Channel to be notified when the challenge is open and to keep updated about the latest information and details about this data challenge.

What’s involved?
On April 19, 2023, teams will be invited to register and submit a short summary of the research they intend to undertake with the data (and Expression of Interest or EOI). The EOIs will be reviewed and teams will be given access to the data for a 30-day window, during which solutions must be submitted.

These submissions will be reviewed by a panel of judges and finalists selected. Finalists will have the opportunity to pitch their idea to a panel of judges via Zoom and the prize winners will be chosen.

Winners will be invited to submit a project abstract to ECCMID 2024.

Rebecca Li speaks at Duke-Margolis Center for Health Policy event

Vivli Executive Director, Rebecca Li, spoke at the Duke-Margolis Center for Health Policy event entitled “Data Capture to Measure, Track, and Improve Antibiotic Use” on March 2nd. She took part in the panel discussion for ‘Policy Approaches to Improve Data Capture for Antibiotic Use’ which discussed the need for the expansion of programs to capture antimicrobial resistance surveillance data, and the barriers stakeholders encounter in gathering evidence for novel antibiotics.

Vivli team authors new publication in GARDP’s REVIVE newsletter

Vivli Executive Director Rebecca Li and Antimicrobial Development Consultant Patricia Bradford recently authored a Viewpoint article entitled “Access to industry antimicrobial resistance (AMR) susceptibility surveillance data” in the GARDP REVIVE newsletter. This paper aims to raise awareness of the availability of high-quality AMR susceptibility data collected from surveillance programs by the pharmaceutical industry. These data are freely available and can be requested through the AMR Register by researchers wishing to advance the fight against antimicrobial resistance.

Vivli Executive Director Dr. Rebecca Li Speaking at the PACCARB September Public Meeting (Innovation Spotlight)

Vivli’s Executive Director, Dr. Rebecca Li, spoke at The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) Public Meeting on September 13th for the Innovation Spotlight, on the topic “AMR Register – An Innovative platform for sharing industry surveillance data”. Dr. Li spoke alongside other companies with innovations in antimicrobial resistance. View Dr. Li’s slides here.

This meeting of PACCARB aimed to “identify key issues and critical policy gaps through a series of facilitated discussions examining a hypothetical large-scale disease outbreak scenario based on historic examples and estimates of future AMR outbreaks.”

Further information about the meeting can be found here.

Media Coverage and Social Media Update

Media Roundup:

Social Media:

Pablo-David Rojas on Twitter: “Here a valuable and powerful tool, data-driven and very useful to tackle #AntimicrobialResistance”

Nadine Hillock on Twitter: ”Fantastic initiative! 👏👏 AMR data sharing platform for researchers to access resistance data held by industry”

Damiano de Felice on Twitter: “Kudos to @Wellcome_AMR and @VivliCenter.It is great to see that the #AMRregister has become a reality”

CIDRAP-ASP on Twitter: “New interview! @cvdall speaks with Dr @rebeccali2006 about the launch of @VivliCenter’s AMR Register, which allows access to raw antibiotic susceptibility data collected by pharmaceutical and biotech companies”

AMR Action Fund on Twitter: “Great Q&A btwn @cvdall and @VivliCenter’s Rebecca Li about the newly launched AMR Register, which is supported by our portfolio co @VenatorxPharma and several of our investors incl @pfizer, @GSK, @JNJGlobalHealth, @Merck, @SHIONOGI_JP https://cidrap.umn.e”

Pfizer Medical on Twitter: “We’re pleased to lead the way as a founding contributor of antimicrobial surveillance raw data to @VivliCenter AMR Register, enabling key decision makers access to trends in resistance #AMR”

Merck on Twitter: “We are proud to include our SMART surveillance program in the new #AMR Register from @VivliCenter, helping preserve antibiotics for future generations. Learn more:”

Francesca on Twitter: “Wow it is fantastic to see this becoming reality and with so many contributing companies @Wellcome_AMR @VivliCenter”

Venatorx Pharmaceuticals on Twitter: “Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance. Log on and explore the Register today!! @VivliCenter @GSK @pfizer @Merck @JNJGlobalHealth @SHIONOGI_JP @ParatekPharma @ViatrisInc

Karla Childers on Twitter: “Congratulations to @VivliCenter for the launch of the AMR register! It was an honor to be part of the event today.”

CIDRAP-ASP on Twitter: “Today, @VivliCenter launched the Antimicrobial Resistance Register, which makes it possible for biopharmaceutical companies to share susceptibility data on infection-causing pathogens for the first time ever in one online platform”

Venatorx on LinkedIn: “ATTENTION: Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance”

Jeevan John on LinkedIn: “Insight has partnered again with nonprofit Vivli in its launch of an AMR data-sharing platform to help clinical researchers tackle the problem.”

Health Europa on LinkedIn: “Leading pharmaceutical companies have joined forces to share surveillance data on antibiotic-resistant bacteria to tackle the global threat of antimicrobial resistance (AMR).”

Robert Kane on LinkedIn: “The World Health Organization cautions that people’s growing resistance to antibiotics puts us at risk to future pandemics. Insight’s effort to help nonprofit data-sharing organization Vivli launch a new clinical research platform unites the work of the world’s sharpest researchers looking to solve this issue.”


Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance

Leading biopharmaceutical companies join Vivli’s new global register to accelerate research into antibiotic resistant bacteria

Cambridge, MA –The Antimicrobial Resistance Register, unveiled today by the nonprofit organization Vivli, makes it possible for biopharmaceutical companies to share susceptibility data on infection causing pathogens for the first time ever in one online platform, marking a critical step in combating the growing global health threat of antimicrobial resistance. With the active participation from leading pharmaceutical and biotech enterprises, researchers will be able to use the AMR Register to translate masses of antimicrobial resistance surveillance data into meaningful action that saves lives and preserves antibiotics for future generations.

Infections caused by antimicrobial-resistant bacteria are on the rise after years of overprescribing antibiotics. Now, illnesses that were once easily treatable with antibiotics are becoming more difficult to cure, and infections caused by antibiotic-resistant bacteria cost billions in avoidable healthcare dollars. According to latest figures from the GRAM report, almost 5 million people died worldwide with an antimicrobial resistant infection. If left unchecked, the scale of antimicrobial resistance will quickly outpace what we have experienced with COVID-19, with deaths rising to 10 million per year by 2050, according to the United Nations.

Biopharmaceutical companies routinely conduct surveillance on all new antimicrobials to monitor susceptibility to pathogens of interest, generating large volumes of high-quality data. Currently, there is no easy way for researchers to access this raw data or combine and analyze multiple datasets from industry. The AMR register will make it easy for biopharmaceutical organizations to securely share their data with researchers, national governments, and multi-lateral organizations such as the United Nations, CDC and the World Health Organization. With robust, reliable industry data, all accessible in one place, scientists will be able to better map key patterns of resistance and identify the emergence of new antibiotic resistant pathogens. Research insights will also inform decision-making around use of antimicrobials, shape policies aimed at halting the spread of resistant pathogens, and spur innovation around new antimicrobial drugs.

“Our understanding of how to control antimicrobial resistant infections and how best to protect human health hinges on better access to surveillance data. Now, with the AMR Register we have an early warning system for one of the greatest public health threats we face,” said Chair of the AMR Register Scientific Advisory Board Marc Mendelson, PhD, Professor of Infectious Diseases and Head of the Division of Infectious Diseases & HIV Medicine at Groote Schuur Hospital, University of Cape Town. “Biopharmaceutical company data is a vital missing link in AMR surveillance, making the research enabled by the AMR register critical to mitigating the AMR pandemic and protecting the effectiveness of antibiotics, now and in the future.”

Companies that have committed to contributing their data to the AMR Register include Pfizer, GSK, Johnson & Johnson, Merck, Paratek Pharmaceuticals, Shionogi & Co., Ltd., and Venatorx Pharmaceuticals.

In 2016, over 100 biopharmaceutical companies and trade associations signed The Davos Declaration on Antibiotic Resistance and later released the Industry Roadmap for Progress on Combating Antimicrobial Resistance ahead of the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance, committing to sharing surveillance data to make it accessible to public health bodies and healthcare professionals. With the AMR Register, industry can now fulfill those commitments, helping contain the risk of AMR and advance scientific knowledge.

“We need urgent action to avert a wave of antibiotic-resistant bacteria,” said Vivli’s Executive Director Rebecca Li, PhD. “By making data openly available, industry is making a crucial contribution to furthering science and helping us get ahead of the next pandemic.”

The AMR Register is guided by a Scientific Advisory Board of influential leaders in antimicrobial resistance and global health, including Henry Kajumbula, MD of Makerere University College of Health Sciences; Trudie Lang of the Nuffield Department of Medicine; Marc Mendelson, PhD, of Groote Schuur Hospital, University of Cape Town; Arjun Srinivasan, MD, from the Centers for Disease Control and Prevention; Janet Midega, PhD, from Wellcome; and Andy Stergachis, PhD, of the University of Washington. The AMR Register was made possible with an initial seed grant from the Wellcome Trust.

Learn more at

Statements from AMR Register Members and Supporters


“Antimicrobial resistance poses a profound threat to lives and livelihoods around the world. Getting ahead of this threat needs action on many fronts – from using existing antibiotics wisely to researching potential new antibiotics; and deploying vaccines to help prevent infection,” said John Billington, head of health security policy and advocacy at GSK. “Surveillance and data-sharing are central to these efforts. The AMR Register will help build our collective understanding of how pathogens are evolving and what is needed to outwit them. Building on GSK’s commitments to data transparency, we are pleased to support the AMR Register by sharing data from our long-running SOAR study, which tracks community-acquired respiratory infections.”

FROM MERCK (known as MSD outside of the United States and Canada)

“For more than two decades, Merck has been conducting ongoing surveillance as part of our global Study for Monitoring Antimicrobial Resistance Trends (SMART) program and working to make the data more widely available,” said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, Global Clinical Development, Merck Research Laboratories. “The launch of the AMR Register helps Merck take that commitment a step further, making this critical data even more accessible to partners around the world to help us all make faster, smarter, data-driven decisions in our collective fight against the urgent threat of AMR.”


“The Vivli AMR initiative aligns with Paratek’s core values and our commitment to support public and private partnerships that enable greater attention to the urgent and growing worldwide public health threat of antimicrobial resistance,” said Alisa W. Serio, PhD, Senior Director, Microbiology, Paratek. “The Vivli platform will be an immensely valuable resource for independent researchers, governments, and global organizations, where robust curated antimicrobial susceptibility data can be found in one place. It is our hope that this collaborative data-sharing effort helps drive further innovation, advances in antimicrobial stewardship practices and improved patient outcomes.”


“Access to surveillance data and trends in antimicrobial resistance allows key decision makers to better adapt antimicrobial stewardship programs to help combat the spread of resistant pathogens,” said Pol Vandenbroucke, Chief Medical Officer, Pfizer Hospital. “At Pfizer, we are driven by our desire to improve global public health and are encouraged to see the collective action the industry is taking to help curb the growing threat of AMR. As the first company to provide open-access to raw surveillance data through our innovative ATLAS surveillance program, Pfizer has a longstanding commitment to antimicrobial stewardship and so we are pleased to again lead the way as a founding contributor to Vivli’s AMR Register.”


“Venatorx has been conducting global surveillance of drug-resistant clinical isolates since 2018, as part of our efforts to support antibacterial drug development” said Greg Moeck, Ph.D., Senior Vice President, Microbiology at Venatorx. “Today, we are excited to announce, and be a part of, this significant collaborative initiative that will enhance and centralize access to high-quality AMR surveillance data across multiple datasets around the globe. Vivli’s AMR Register is vital to support educational and scientific communications on the AMR burden and emerging resistance, as well as global public health at large.”


“Centralized disclosure of antimicrobial surveillance data is very important from the drug-resistance-monitoring perspective.” stated Ms. Takuko Sawada, Director of the Board, Executive Vice President, Shionogi & Co., Ltd. “Shionogi believes that Vivli’s AMR Register is the essential initiative to address antimicrobial stewardship and expansion of AMR on the global level.”


“Covid-19 has demonstrated the importance of high quality, readily accessible data to all elements of an effective public health response,” said Tim Jinks, Head of Infectious Disease Intervention at Wellcome. “Drug-resistant infections are no exception. The Antimicrobial Resistance Register will play a critical role in providing open-access data that supports identifying both the emergence of new antibiotic resistant pathogens and where they are spreading. This has a breadth of benefits, including informing the stewardship of existing antimicrobials and guiding the innovation of new treatments, diagnostics and vaccines.”

About Vivli

Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. Data sharing initiatives include the Antimicrobial Resistance Register for AMR surveillance data and the Vivli Platform for clinical trial data. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit and follow us on Twitter @VivliCenter.

About Wellcome

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health.